Document is current
Any future updates will be listed below
-
Authors
Karmakar, Subir
Ismail, Nevien
Oliveira, Fabiano https://orcid.org/0000-0002-7924-8038
Oristian, James
Zhang, Wen Wei https://orcid.org/0000-0003-1996-876X
Kaviraj, Swarnendu
Singh, Kamaleshwar P.
Mondal, Abhishek
Das, Sushmita
Pandey, Krishna
Bhattacharya, Parna
Volpedo, Greta
Gannavaram, Sreenivas https://orcid.org/0000-0002-6557-8220
Satoskar, Monika
Satoskar, Sanika
Sastry, Rajiv M.
Oljuskin, Timur https://orcid.org/0000-0001-5494-2237
Sepahpour, Telly
Meneses, Claudio
Hamano, Shinjiro
Das, Pradeep
Matlashewski, Greg https://orcid.org/0000-0002-8971-5525
Singh, Sanjay
Kamhawi, Shaden https://orcid.org/0000-0003-4304-636X
Dey, Ranadhir https://orcid.org/0000-0003-0069-7867
Valenzuela, Jesus G. https://orcid.org/0000-0002-5589-9450
Satoskar, Abhay
Nakhasi, Hira L. https://orcid.org/0000-0003-4941-1620
-
Funding
Funding for this research was provided by:
Fonds de recherche du Québec – Santé
Intramural Research Program of the NIH
Global Health Innovative Technology Fund
Global Health Innovative Technology Fund; Intramural funding from CBER, FDA
- License Information
-
More Information
Article History
Received: 24 March 2021
Accepted: 7 July 2021
First Online: 30 July 2021
Competing interests
: The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania</i> species with the Centrin gene deletion (US 7,887,812 and US 8,877,213). All other authors declare they have no competing interests.
